Generic Xiidra Availability
Last updated on Apr 10, 2025.
Xiidra is a brand name of lifitegrast ophthalmic, approved by the FDA in the following formulation(s):
XIIDRA (lifitegrast - solution/drops;ophthalmic)
-
Manufacturer: BAUSCH AND LOMB INC
Approval date: July 11, 2016
Strength(s): 5% [RLD]
Is there a generic version of Xiidra available?
No. There is currently no therapeutically equivalent version of Xiidra available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xiidra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
LFA-1 inhibitor formulations
Patent 11,058,677
Issued: July 13, 2021
Inventor(s): Newman Mary & Hunke William
Assignee(s): Novartis AGThe present invention provides formulations, methods and kits for the treatment of dry eye diseases. In particular, stabilized pharmaceutical compositions comprising the compound of Formula 1 are described herein for a variety of uses including the treatment of dry eye syndrome. In one aspect, methods and ingredients for improving the stability of compositions of the compound of Formula 1 are described.
Patent expiration dates:
- December 18, 2033✓
- December 18, 2033
-
Modulators of cellular adhesion
Patent 7,314,938
Issued: January 1, 2008
Inventor(s): Shen; Wang et al.
Assignee(s): Sunesis Pharmaceuticals, Inc. (South San Francisco, CA)The present invention provides compounds having formula (I): ##STR00001## and pharmaceutically acceptable derivatives thereof, wherein R.sub.1-R.sub.4, n, p, A, B, D, E, L and AR.sup.1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
Patent expiration dates:
- March 10, 2025✓✓
- March 10, 2025
-
Compositions and methods for treatment of eye disorders
Patent 8,084,047
Issued: December 27, 2011
Inventor(s): Shen; Wang et al.
Assignee(s): Sarcode Bioscience Inc. (Brisbane, CA)The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Patent expiration dates:
- May 17, 2026✓✓
- May 17, 2026
-
Compositions and methods for treatment of eye disorders
Patent 8,168,655
Issued: May 1, 2012
Inventor(s): Gadek Thomas & Burnier John
Assignee(s): SARcode Bioscience Inc.The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Patent expiration dates:
- May 9, 2029✓
- May 9, 2029
-
Crystalline pharmaceutical and methods of preparation and use thereof
Patent 8,367,701
Issued: February 5, 2013
Inventor(s): Burnier John & Gadek Thomas & Naud Frederic
Assignee(s): SARcode Bioscience Inc.Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
Patent expiration dates:
- April 15, 2029✓✓
- April 15, 2029
-
Compositions and methods for treatment of eye disorders
Patent 8,592,450
Issued: November 26, 2013
Inventor(s): Gadek Thomas & Burnier John
Assignee(s): SARcode Bioscience Inc.The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Patent expiration dates:
- May 17, 2026✓
- May 17, 2026
-
Crystalline pharmaceutical and methods of preparation and use thereof
Patent 8,927,574
Issued: January 6, 2015
Inventor(s): Burnier John
Assignee(s): SARcode Bioscience Inc.Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
Patent expiration dates:
- November 12, 2030✓
- November 12, 2030
-
LFA-1 inhibitor and methods of preparation and polymorph thereof
Patent 9,085,553
Issued: July 21, 2015
Inventor(s): Zeller James Robert & Venkatraman Sripathy & Brot Elisabeth C. A. & Iyer Subashree & Hall Michael
Assignee(s): SARCODE BIOSCIENCE, INC.Methods of preparation and purification of a compound of Formula I, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed.
Patent expiration dates:
- July 25, 2033✓
- July 25, 2033
-
Crystalline pharmaceutical and methods of preparation and use thereof
Patent 9,353,088
Issued: May 31, 2016
Inventor(s): Burnier John
Assignee(s): SARcode Bioscience Inc.Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
Patent expiration dates:
- October 21, 2030✓
- October 21, 2030
-
Crystalline pharmaceutical and methods of preparation and use thereof
Patent 9,447,077
Issued: September 20, 2016
Inventor(s): Burnier John & Gadek Thomas & Naud Frederic
Assignee(s): SARcode Bioscience Inc.Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
Patent expiration dates:
- April 15, 2029✓
- April 15, 2029
-
Crystalline pharmaceutical and methods of preparation and use thereof
Patent 9,890,141
Issued: February 13, 2018
Inventor(s): Burnier John
Assignee(s): SARCODE BIOSCIENCE INC.Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
Patent expiration dates:
- October 21, 2030✓
- October 21, 2030
More about Xiidra (lifitegrast ophthalmic)
- Compare alternatives
- Pricing & coupons
- Reviews (449)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: ophthalmic anti-inflammatory agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
